Emory Healthcare · Clinical Protocol

Placenta Accreta
Spectrum

Invasive Placental Disease Management

ACOG Consensus No. 7 SMFM 2023 Emory Healthcare 2026

Effective Date: 02/12/2026 · Applicable Facilities: EDH, EJCH, EUHM

Section 1 · Overview

Scope & Purpose

Section 1 · Definition

What is PAS?

A spectrum of abnormal placental adherence and invasion into the uterine wall. Formerly known as morbidly adherent placenta.

🔵 Accreta Villi attach to
myometrium
🟣 Increta Villi invade
myometrium
🔴 Percreta Villi penetrate
through serosa

ACOG/SMFM Obstetric Care Consensus No. 7 (2018) · Emory Healthcare Policy (2026)

Section 1 · Depth of Invasion

Placenta Accreta

Definition
Chorionic villi attach directly to the myometrium without invasion. No intervening decidua basalis.
Clinical Significance
Most common form (~75–78%). Placenta does not separate normally at delivery.
Section 1 · Depth of Invasion

Placenta Increta

Definition
Chorionic villi invade the myometrium but do not penetrate the uterine serosa.
Clinical Significance
~17% of PAS cases. Greater risk of hemorrhage than accreta alone.
Section 1 · Depth of Invasion

Placenta Percreta

Definition
Villi penetrate through the uterine serosa and may invade adjacent organs (bladder, bowel).
Clinical Significance
~5% of PAS. Highest morbidity. Requires urology/colorectal surgical involvement.
Section 1 · Pathophysiology

Etiology & Pathophysiology

ACOG/SMFM Obstetric Care Consensus No. 7 (2018)

Section 1 · Epidemiology

Rising Incidence

1 in 272
Current US rate
(National Inpatient Sample, 2016)
1 in 533
Rate from
1982–2002
1 in 2,510
Rate in
1970s–1980s

ACOG/SMFM Obstetric Care Consensus No. 7 (2018)

Section 2

Risk Factors &
Diagnosis

Identifying patients at risk and confirming the diagnosis antenatally

Section 2 · Risk Factors

Primary Risk Factor:
Prior Cesarean Delivery

Prior Cesarean Deliveries PAS Risk (with Placenta Previa)
03%
111%
240%
361%
≥467%

ACOG/SMFM Obstetric Care Consensus No. 7 (2018)

Section 2 · Risk Factors

Additional Risk Factors

Uterine History
Prior uterine surgeries, curettage, or Asherman syndrome
Maternal Factors
Advanced maternal age, multiparity
Placental Location
Placenta previa is a major independent risk factor

ACOG/SMFM Obstetric Care Consensus No. 7 (2018)

Section 2 · Diagnosis

Antenatal Diagnosis

ACOG/SMFM Obstetric Care Consensus No. 7 (2018)

Section 2 · Ultrasound

Ultrasound Features

Gray-Scale Findings
Multiple vascular lacunae within placenta
Loss of normal hypoechoic zone
Retroplacental myometrial thickness <1 mm
Abnormal uterine serosa–bladder interface
Doppler Findings
Turbulent lacunar blood flow (most common)
Increased subplacental vascularity
Gaps in myometrial blood flow
Vessels bridging placenta to uterine margin

SMFM PAS Ultrasound Marker Task Force (2021) · ACOG/SMFM Consensus No. 7 (2018)

Section 2 · Imaging

MRI: Adjunct Imaging

When to Consider MRI
Posterior placenta previa · Indeterminate ultrasound · Suspected percreta with organ invasion
Limitations
More expensive · Less available · Expertise limited · Does not clearly improve on ultrasound in most cases

ACOG/SMFM Obstetric Care Consensus No. 7 (2018)

Section 3

Care Coordination &
Planning

Multidisciplinary team assembly and pre-operative preparation

Section 3 · Care Coordination

Core Care Team

🤱 Nursing
Clinical coordination lead
👩‍⚕️ MFM
Maternal-Fetal Medicine specialist
💉 Anesthesia
Neuraxial or general anesthesia planning
👶 NICU
Neonatal intensive care unit
🩸 Blood Bank
Massive transfusion protocol readiness

Consultation by second trimester or as soon as diagnosis is made · Emory Healthcare Protocol (2026)

Section 3 · Care Coordination

Augmented Care Team

🔬 Gyn-Oncology
Retroperitoneal dissection support
🏥 ICU
Postoperative critical care planning
🩻 Interventional Radiology
Rare adjunct procedures (selective use)
🫀 Urology
Suspected bladder/ureteral involvement
🔪 Trauma / General / Colorectal Surgery
Suspected bowel involvement
Section 3 · Facility Requirements

Level of Care

ACOG/SMFM Recommendation
Delivery at a Level III or IV maternal care facility. Continuously available staff with PAS expertise.
Required Infrastructure
Interdisciplinary critical care team · Blood bank with massive transfusion protocol · Strong nursing leadership

ACOG SMFM Obstetric Care Consensus No. 7 (2018)

Section 3 · Delivery Planning

Timing of Delivery

34–35+6
Weeks of gestation
Recommended delivery window

ACOG/SMFM Consensus No. 7 (2018) · RCOG Green-top Guideline 27a (2018)

Section 3 · Care Timeline

Antenatal Care Timeline

1
1st TrimesterIdentify risk factors; early ultrasound evaluation
2
2nd TrimesterMultidisciplinary team consultation; confirm diagnosis
3
3rd TrimesterSchedule OR; obtain consent; pre-op assessment
4
34–35+6 wksPlanned cesarean hysterectomy
5
PostpartumICU / recovery; surveillance if conservative management
Section 3 · Consent

Informed Consent

Emory Healthcare Protocol (2026)

Section 4

Intraoperative
Management

Surgical approach, hemorrhage preparedness, and goal-directed therapy

Section 4 · Surgical Approach

General Surgical Approach

Standard Approach
Planned cesarean hysterectomy with placenta left in situ after fetal delivery. Avoid attempted placental removal.
Conservative Management
Uterus-sparing strategies only in highly selected cases at centers with specific expertise and with informed consent.

ACOG/SMFM Consensus No. 7 (2018) · FIGO Consensus Guidelines (2018)

Section 4 · Pre-Incision

Pre-Incision Team Huddle

Emory Healthcare Protocol (2026)

Section 4 · Pre-operative Labs

Labs & Vascular Access

Laboratory Studies
CBC · CMP · Type and cross for 4 units PRBC
Maintain active T&S / T&C every 72 hours (admitted patients)
Vascular Access
2 large bore IVs · Consider arterial line · Central venous access only as clinically indicated

Emory Healthcare Protocol (2026)

Section 4 · Hemorrhage Preparedness

Hemorrhage Preparedness

🩸 Cell Saver
Connected and used throughout procedure
🌡️ Fluid Warmer
In-line fluid warmer required
⚡ Rapid Infuser
Available in OR; prime if needed
📊 QBL Monitoring
Quantitative blood loss assessment every 30 minutes
🧪 TEG/ROTEM
Goal-directed therapy guided by labs/TEG/ROTEM when available
💊 Uterotonics
Oxytocin, methylergonovine, carboprost, misoprostol, calcium

Emory Healthcare Protocol (2026)

Section 4 · Transfusion Management

Goal-Directed Transfusion Targets

Fibrinogen
≥ 200
mg/dL
Hemoglobin
> 7
g/dL
Platelets
> 50,000
per µL

Active transfusion management early for uncontrolled bleeding

Emory Healthcare Protocol (2026)

Section 4 · Pharmacologic Adjuncts

Tranexamic Acid (TXA)

Dosing Protocol
1 g TXA at 1 L blood loss
Repeat dose at 30 minutes if hemorrhage continues
Availability
Ensure TXA is available and accessible in the OR prior to incision

Emory Healthcare Protocol (2026)

Section 5

Adjunct Procedures &
Post-Operative Care

Interventional radiology, ureteral stents, and postoperative planning

Section 5 · Adjunct Procedures

Interventional Radiology (IR)

Not Recommended
Routine pre-op prophylactic balloon occlusion is NOT recommended — evidence does not support routine use
Selective Use
May be considered in suspected percreta with extra-uterine organ invasion at experienced centers after multidisciplinary discussion

Emory Healthcare Protocol (2026) · ACOG/SMFM Consensus No. 7 (2018)

Section 5 · Adjunct Procedures

Ureteral Stents

Not Routinely Recommended
Evidence does not demonstrate reduced ureteral injury with routine use
Consider When
Strong suspicion of bladder or parametrial invasion to facilitate identification, based on surgeon preference and anatomy

Emory Healthcare Protocol (2026)

Section 5 · Conservative Management

Conservative Management

Emory Healthcare Protocol (2026) · FIGO Consensus Guidelines (2018)

Section 5 · Post-Operative

Post-Operative Care

ICU Planning
Pre-planned ICU admission as part of augmented care coordination. Intensivist involvement as indicated.
Monitoring
Continued hemorrhage surveillance · Coagulation monitoring · Wound and organ injury assessment

Emory Healthcare Protocol (2026)

Summary

Key Takeaways

References

Evidence Base

Source Year Key Contribution
ACOG/SMFM Obstetric Care Consensus No. 7 2018 Diagnosis, delivery timing (34–35+6 wks), cesarean hysterectomy standard
SMFM PAS Ultrasound Marker Task Force 2021 Standardized sonographic markers and ultrasound examination approach
FIGO Consensus Guidelines on PAS 2018 Conservative and non-conservative surgical management, terminology
RCOG Green-top Guideline 27a 2018 Steroid timing at 34–35+6 wks, follow-up imaging
Emory Healthcare Invasive Placental Disease Policy 2026 Institutional protocol for EDH, EJCH, EUHM
← OpenMFM Library